Results 21 to 30 of about 9,620 (164)

Canakinumab for systemic-onset juvenile idiopathic arthritis/Still’s disease—effectiveness and safety data from the BiKeR registry

EULAR Rheumatology Open
: Objectives: In Germany, canakinumab is approved for the treatment of refractory systemic juvenile idiopathic arthritis (sJIA)/Still’s disease. This study assesses the experience of sJIA/Still’s disease patients treated with canakinumab in clinical ...
Gerd Horneff, Tilmann Kallinich, Kirsten Minden, Frank Dressler, Markus Hufnagel, Frank Weller-Heinemann, Ariane Klein   +6 more
doaj   +1 more source

Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience

Pediatric Rheumatology Online Journal, 2023
Background There is no clear data on the optimal duration of treatment with anti-interleukin-1 drugs in colchicine-resistant familial Mediterranean fever patients, as well as on the dose interval.
Gülşah Kavrul Kayaalp, Şengül Çağlayan, Fatma Gül Demirkan, Vafa Guliyeva, Gülçin Otar Yener, Kübra Öztürk, Ferhat Demir, Semanur Özdel, Mustafa Çakan, Hafize Emine Sönmez, Betül Sözeri, Nuray Aktay Ayaz   +11 more
doaj   +1 more source

Building a Framework for Sexual and Reproductive Health Care in the Rheumatology Context: Content and Approaches

Arthritis Care &Research, EarlyView.
People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley   +1 more source

Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis

International Journal of Immunopathology and Pharmacology, 2021
Introduction The fully-human monoclonal anti-interleukin (IL)-1β antibody canakinumab may inhibit the production of inflammatory mediators in patients with coronavirus disease 2019 (COVID-19) and the hyperinflammatory response potentially leading to ...
Antonio Mastroianni, Sonia Greco, Luciana Chidichimo, Filippo Urso, Francesca Greco, Maria V Mauro, Valeria Vangeli   +6 more
doaj   +1 more source

Encoded Cell‐Material Interactions to Reroute Cytokine Signaling for Regenerative Medicine

Advanced Healthcare Materials, EarlyView.
We present native MATRIX (Material Activated To Regulate Inducible gene eXpression), a co‐engineered material‐cell platform. Surfaces functionalized with antibodies for endogenous soluble ligands (e.g., IL‐1β or IL‐6) capture and immobilize ligands for presentation to a cognate, engineered synthetic Notch receptor, releasing a transcription factor (TF)
Zachary M. Eidman, Jhanvi Sharma, Joanne C. Lee, Nicholas F. Schulze, Hannah J. Brien, Kevin C. Corn, Marjan Rafat, Jonathan M. Brunger   +7 more
wiley   +1 more source

Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review

Journal of Dermatological Treatment
Aims To evaluate the efficacy and adverse events of canakinumab in the treatment of pyoderma gangrenosum (PG).Methods We report two cases of refractory PG treated with canakinumab after failing multiple therapies.Results A 44-year-old female achieved ...
Howard Jie Yang, William Spratt, Francis Yi Xing Lai, Senhong Lee   +3 more
doaj   +1 more source

Administration of the Interleukin-1 Inhibitor Canakinumab in Children with Autoinflammatory Diseases and Systemic Juvenile Arthritis: the Report for Case Series

Вопросы современной педиатрии, 2016
In Russia, the interleukin-1 inhibitor canakinumab (fully human monoclonal antibodies to interleukin-1) is increasingly used for treating autoinflammatory diseases and systemic juvenile arthritis (sJIA).
S. O. Salugina, M. I. Kaleda, Ye. S. Fyodorov, I. P. Nikishina   +3 more
doaj   +1 more source

Pathological Mechanism‐Inspired Biomimetic Nano‐Senotherapy for Reversing Experimental Atherosclerosis in ApoE−/− Mice

Advanced Science, EarlyView.
The biomimetic self‐assembly nanomedicine reversing atherosclerosis via senotherapy strategy. ABSTRACT The greatest challenge in atherosclerosis (AS) management lies in achieving lesion reversal, not merely slowing progression. Senescent cell accumulation—driven by continuous generation and apoptotic resistance—perpetuates plaque pathology and ...
Yuhan Tian, Yanrui Yang, Qiuyu Li, Ying Hu, Qin Hu, Shasha Ran, Siyu Zhou, Xiujuan Yang, Shanshan Li, Qixiong Zhang   +9 more
wiley   +1 more source

Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China

Pediatric Rheumatology Online Journal
Objective Cryopyrin-associated periodic syndrome (CAPS) is characterized by excessive IL-1β release resulting in systemic and organ inflammation. As an anti-IL-1 agent, canakinumab has been approved with all CAPS phenotypes in USA and European countries.
Xiaona Zhu, Jiaqi Fan, Yanyan Huang, Yongbin Xu, Zhi Yang, Ruohang Weng, Ying Luo, Jun Yang, Tingyan He   +8 more
doaj   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source